Today, on #MensHealthDay, let’s raise awareness of men-biased autoimmune diseases like axial spondylarthritis, and women-biased autoimmune disease in men! www.internationalmensday.info

Helga Lechner-Radner joined ORF’s Bewusst gesund to discuss “Leben mit Rheuma”. She highlighted that rheumatic diseases go far beyond joint pain, early diagnosis and modern therapy can truly change lives. 🎥 onepager.orf.at/bewusstgesun...

I recently shared my thoughts on Austria’s strong global role in rheumatology in my recent Schmerz Nachrichten interview, from @eular.org initiatives to digital innovation and equity in care. Grateful to all who make this collaboration possible. 🇦🇹 link.springer.com/article/10.1...

At the Dresden Symposium on Autoantibodies 2025, Daniela Sieghart presented on biomarkers for RA treatment response, highlighting EU projects @squeezeproject.bsky.social & @autopix.bsky.social. Our division drives precision medicine forward, tailoring care through innovative biomarkers.

New in Journal of Autoimmunity: our study on FAPI PET/CT in myositis-related ILD, led by Kastriot Kastrati & Peter Mandl. Findings show FAPI uptake predicts progression better than standard tools, promising step for personalized care. 📖 doi.org/10.1016/j.ja...

🚀 Meet our supportive partner: @inmusc.bsky.social  #InMusc is a Spanish consultancy that helps transform ideas into impact through research and #methodology training. Their mission is to make research collaborations agile, relevant, and meaningful.

📢 New from our Division of Rheumatology: Peter Mandl on the expanding role of ultrasound in rheumatology - beyond joints to glands, vessels, lungs & muscles. Real-time, radiation-free imaging for diagnosis & management. 🎥 www.youtube.com/watch?v=XgOO...

Our study on how global recruitment patterns affect placebo response in RA trials has gained broad Austrian media coverage (ORF, NÖN, SN & more). Great to see interest in how trial design impacts fair evaluation of new therapies! 🔗 science.orf.at/stories/3231...

Two new papers from our division show that recruiting RA & PsA trial patients in less affluent regions increase placebo rates - likely from limited treatment access. Trial design must adapt. RA: doi.org/10.1016/j.ar... PsA: doi.org/10.1002/art....

Join the 9th EULAR Course on Immunology 2026, a highly interactive course focused on key immunology concepts and practical research project design. 📅 6-7 February 2026 📍Amsterdam, Netherlands 🔔Registration deadline: 2 November 2025 Register here: https://pulse.ly/nul3x4sazs #eularEDUCATION

Can we collect meaningful patient-reported outcomes in rheumatology using a smartphone app? 📱 Our latest study says YES. Check it out in RMD Open: 👉 doi.org/10.1136/rmdo...

‪Discover more of @danielaletaha.bsky.social‬, @meduniwien.ac.at and past ‪@eular.org‬ president's thoughts on EMJ: www.emjreviews.com/rheumatology...

Join the 8th EULAR Imaging Course 2026, an intensive, hands-on course covering key imaging techniques in rheumatology, from X-ray to MRI and ultrasound. 📅5-6 February 2026 📍Amsterdam, Netherlands 🔔Registration deadline: 2 November 2025 Register here: https://pulse.ly/5a9ni8gnzs #eularEDUCATION

📸 Behind every project is a team. During the EULAR 2025 Congress in Barcelona, we had the pleasure to meet with members of six research consortia: HIPPOCRATES, SQUEEZE, STRATA-FIT, MDR-RA, PerPrev-CID, and AutoPiX. 👉 Interested in partnering with us? Learn more here: https://pulse.ly/58wj8jwuui

🚀Join us on our #EULAR and #EMEUNET Webinar: "Gender-specific differences in rheumatic diseases" 💻Wednesday, 13 Aug 2025, 18:00-18:45 CEST Register here👉https://pulse.ly/lqp4vkeeod #eularEMEUNET #Rheumatology

Can women with systemic autoimmune rheumatic diseases pass on robust immunity to their babies? Turns out - yes. 👶🛡️ Proud to share our latest collaborative study on maternal antibody transfer in the Journal of Autoimmunity: doi.org/10.1016/j.ja...

At KinderUni 2025, our division of Rheumatology @meduniwien.ac.at explored the fascinating world of autoimmunity with Vienna’s youngest scientists. Huge thanks to our amazing team for inspiring future researchers! 👉 kinderuni-anmeldung.at/event.php?ev...

Idiopathic #inflammatorymyopathies are rare #autoimmunediseases in which the #immunesystem attacks the body's own #musclecells. A team from #MedUniVienna has systematically described the safety and efficacy of targeted #immunotherapy in refractory idiopathic inflammatory #myopathies. ⬇️

New review in Joint Bone Spine co-authored by our team highlights ultrasound's expanding role from joints to organ involvement in rheumatic diseases. Read more 👉 www.sciencedirect.com/science/arti...

Great meeting in Stockholm with the @autopix.bsky.social team! Thanks @collectiveminds.bsky.social for hosting. We're advancing AI tools to improve rheumatic care - excited for what’s ahead!

Check out the interview I made within the frame of #EULAR2025 with the talented EMEUNET Newsletter Sub-Committee members Anastasia Madenidou and Victoria Konzett 👇 emeunews.org/2025/06/01/t...

Check out my interview, masterfully led by Valentina Pucino after the plenary session of #EULAR2025 👇 www.youtube.com/watch?v=d6hi...

Proud to showcase the @squeezeproject.bsky.social at #EULAR2025! Visit booth O9 (near Hall 8.1, NPO area) to learn how we’re advancing precision medicine in RA to get the right treatment to the right patient.

Proud of our @autopix.bsky.social at #EULAR2025! Visit us at booth O8 (near Hall 8.1, NPO area) to learn how we’re using AI to advance rheumatic image analysis for better patient care.

And that’s the start of what it’s going to be a very exciting @eular.org Congress! Open ceremony with @danielaletaha.bsky.social #EULAR2025

🎙️ Mark the first of many SQUEEZE talks at #EULAR2025: "Add-on vs. Replacement csDMARDs post-MTX. A European analysis on csDMARD Treatment Choices." Presented by Nils Steinz from Leiden University Medical Center (LUMC) on June 12, at 10:50 am at room A2. #RA #DMARD #PrecisionMedicine

🟣 Today, on International Day of Action for Women’s Health, we reaffirm: women’s health is central to rheumatology - from research to care. Let’s keep pushing forward. may28.org #WomensHealthMatters #Rheumatology #AutoimmuneDiseases #HealthEquity

I was interviewed by my team to share why EULAR 2025 in Barcelona will be exciting—and why you shouldn't miss it!📺 www.youtube.com/watch?v=rvf5... #EULAR2025

Can we prevent rheumatoid arthritis before it starts? Research on preclinical RA suggests early intervention could halt or delay the disease. Could prevention be the future of RA care? Read our latest editorial! 🔗 doi.org/10.1016/j.jb...

Last week was our first meetup with the Patient Research Partners involved in our IHI-funded AutoPiX project! We’re using AI to dig deeper into imaging data in rheumatic diseases care. Big thanks to everyone bringing their voice to the table! 💬🤝 #PatientInvolvement #Rheumatology #AI

Proud to share that Josef S. Smolen has been named a 2024 Highly Ranked Scholar – Lifetime by ScholarGPS, placing him in the top 0.05% worldwide in medicine (tinyurl.com/3kwv6wem). A true inspiration and mentor — congratulations, Josef, particularly from all your academic offspring! 👏

🎧 New on the Digital Rheumatology Network podcast: Our very own Paul Studenic shares his insights from ACR & EULAR, tech trends, and patient empowerment: 🔗 tinyurl.com/3j8ha8ch #DigitalRheumatology #DigitalHealth #EULAR #ACR #FutureOfCare

🎉 Halfway there! Our @SQUEEZE project hits its 2.5-year mark! We've advanced RA treatment with biomarker research, launched 3 clinical trials, and strengthened patient engagement. Exciting progress ahead as we optimize therapies! Stay tuned: tinyurl.com/47uv45ts

Josef Smolen and I co-founded Preferrix to improve clinical trial access. Now live as a Meduniwien spin-off, it connects doctors and trial centers, expanding recruitment beyond specialized clinics and for all patients regardless of where they receive care: tinyurl.com/34659wwc

How should we treat undifferentiated arthritis in 2025? Annette van der Helm-van Mil and I challenge existing paradigms a recent viewpoint. UA is not just "early RA"—today’s patients present differently, with milder disease and frequent remission. Time to rethink treatment. doi.org/10.1016/j.ar...

Check out our new reviews on JAK inhibitors in IMIDs: 📌 Efficacy: 102 RCTs, 21 JAK inhibitors, 51 diseases—strong evidence across IMIDs. 📌 Safety: 209 studies analyzed risks like CV events, infections, malignancies. doi.org/10.1016/j.ar... & doi.org/10.1016/j.ar...

Ich freue mich, mein Interview mit Die ganze WOCHE zu teilen: tinyurl.com/bdzz8ss8 📰 Wie uns künstliche Intelligenz hilft die Behandlung von entzündlichem Gelenksrheuma präziser zu gestalten und wie wir in unserem AutoPiX-Projekt die Auswertung von Bilddaten verbessern: www.autopix-project.eu 🏥🔬

Our Division of Rheumatology hosted its annual General Recess—an inspiring forum for research exchange! This year, we also launched Rheumavation, a 1-minute pitch challenge for innovative ideas. Congrats to our first-ever winners, Marlene Steiner & Lisabeth Emilius! 👏 #Rheumatology #Innovation